Collegium Pharmaceutical Reports Strong Q3 2025 Financial Results

Collegium Pharmaceutical ( (COLL) ) has shared an announcement.

Collegium Pharmaceutical reported strong financial results for the third quarter of 2025, with record net revenue of $209.4 million, a 31% increase year-over-year. The company raised its full-year 2025 guidance, expecting net revenue between $775 to $785 million and adjusted EBITDA between $460 to $470 million. The growth was driven by a 20% increase in Jornay PM prescriptions and a robust performance in its pain portfolio. The company continues to focus on strategic business development and disciplined capital deployment to support patient care and drive shareholder value.

The most recent analyst rating on (COLL) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.

Spark’s Take on COLL Stock

According to Spark, TipRanks’ AI Analyst, COLL is a Neutral.

Collegium Pharmaceutical’s overall stock score is driven by strong earnings call performance and solid financials, despite concerns over high leverage and valuation. The positive outlook from raised guidance and strategic investments supports future growth potential, while technical indicators suggest a neutral market sentiment.

To see Spark’s full report on COLL stock, click here.

More about Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company focused on improving the lives of people with serious medical conditions. It has a leading portfolio of responsible pain management medications and a growing neuropsychiatry business, with Jornay PM® as a key treatment for ADHD. The company is headquartered in Stoughton, Massachusetts.

Average Trading Volume: 403,212

Technical Sentiment Signal: Buy

Current Market Cap: $1.13B

Find detailed analytics on COLL stock on TipRanks’ Stock Analysis page.